Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

OBJECTIVES: Anetumab ravtansine is an antibody-drug conjugate consisting of a fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4. Mesothelin is highly expressed in ovarian cancer. This phase Ib study determines the safety, pharmacokinetics, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Santin, Alessandro D, Vergote, Ignace, González-Martín, Antonio, Moore, Kathleen, Oaknin, Ana, Romero, Ignacio, Diab, Sami, Copeland, Larry J, Monk, Bradley J, Coleman, Robert L, Herzog, Thomas J, Siegel, Jonathan, Kasten, Linda, Schlicker, Andreas, Schulz, Anke, Köchert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Bulat, Iurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086500/
https://www.ncbi.nlm.nih.gov/pubmed/36564099
http://dx.doi.org/10.1136/ijgc-2022-003927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086500/
https://www.ncbi.nlm.nih.gov/pubmed/36564099
http://dx.doi.org/10.1136/ijgc-2022-003927

Ejemplares similares